The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data

Liver cancer is a serious threat to public health and has fairly complicated pathogenesis. Therefore, the identification of key genes and pathways is of much importance for clarifying molecular mechanism of hepatocellular carcinoma (HCC) initiation and progression. HCC-associated gene expression dataset was downloaded from Gene Expression Omnibus database. Statistical software R was used for significance analysis of differentially expressed genes (DEGs) between liver cancer samples and normal samples. Gene Ontology (GO) term enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, based on R software, were applied for the identification of pathways in which DEGs significantly enriched. Cytoscape software was for the construction of protein–protein interaction (PPI) network and module analysis to find the hub genes and key pathways. Finally, weighted correlation network analysis (WGCNA) was conducted to further screen critical gene modules with similar expression pattern and explore their biological significance. Significance analysis identified 1230 DEGs with fold change >2, including 632 significantly down-regulated DEGs and 598 significantly up-regulated DEGs. GO term enrichment analysis suggested that up-regulated DEG significantly enriched in immune response, cell adhesion, cell migration, type I interferon signaling pathway, and cell proliferation, and the down-regulated DEG mainly enriched in response to endoplasmic reticulum stress and endoplasmic reticulum unfolded protein response. KEGG pathway analysis found DEGs significantly enriched in five pathways including complement and coagulation cascades, focal adhesion, ECM–receptor interaction, antigen processing and presentation, and protein processing in endoplasmic reticulum. The top 10 hub genes in HCC were separately GMPS, ACACA, ALB, TGFB1, KRAS, ERBB2, BCL2, EGFR, STAT3, and CD8A, which resulted from PPI network. The top 3 gene interaction modules in PPI network enriched in immune response, organ development, and response to other organism, respectively. WGCNA revealed that the confirmed eight gene modules significantly enriched in monooxygenase and oxidoreductase activity, response to endoplasmic reticulum stress, type I interferon signaling pathway, processing, presentation and binding of peptide antigen, cellular response to cadmium and zinc ion, cell locomotion and differentiation, ribonucleoprotein complex and RNA processing, and immune system process, respectively. In conclusion, we identified some key genes and pathways closely related with HCC initiation and progression by a series of bioinformatics analysis on DEGs. These screened genes and pathways provided for a more detailed molecular mechanism underlying HCC occurrence and progression, holding promise for acting as biomarkers and potential therapeutic targets.

[1]  Adrian V. Lee,et al.  Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. , 2011, The Journal of clinical investigation.

[2]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[3]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[4]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[5]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[6]  T. Greten,et al.  The yin and yang of evasion and immune activation in HCC. , 2015, Journal of hepatology.

[7]  M. Goggins,et al.  Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling , 2005, Clinical Cancer Research.

[8]  E. Chevet,et al.  Integrated endoplasmic reticulum stress responses in cancer. , 2007, Cancer research.

[9]  A. Parsa,et al.  Complement anaphylatoxins as immune regulators in cancer , 2014, Cancer medicine.

[10]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[11]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[12]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[13]  A. Gerger,et al.  Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. , 2015, Anticancer research.

[14]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[15]  K. Katanoda,et al.  Five-year relative survival rate of liver cancer in the USA, Europe and Japan. , 2014, Japanese journal of clinical oncology.

[16]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[17]  Bin Nan,et al.  Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. , 2007, Cancer research.

[18]  B. Rini,et al.  MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. , 2011, International immunopharmacology.

[19]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[20]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[21]  R. Fisher,et al.  Genes Involved in Viral Carcinogenesis and Tumor Initiation in Hepatitis C Virus-Induced Hepatocellular Carcinoma , 2009, Molecular medicine.

[22]  C. Coulouarn,et al.  Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinoma , 2003 .

[23]  Laurie H Glimcher,et al.  The unfolded protein response: integrating stress signals through the stress sensor IRE1α. , 2011, Physiological reviews.

[24]  Y. Watanabe,et al.  Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. , 2008, Liver.

[25]  G. Tamma,et al.  Oxidative Medicine and Cellular Longevity , 2017 .

[26]  L. Hendershot,et al.  The role of the unfolded protein response in tumour development: friend or foe? , 2004, Nature Reviews Cancer.

[27]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[28]  C. Coulouarn,et al.  Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. , 2003, Molecular carcinogenesis.

[29]  Crispin J. Miller,et al.  Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis , 2005, Bioinform..

[30]  John D Lambris,et al.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. , 2012, Neoplasia.

[31]  Sahil Mittal,et al.  Epidemiology of hepatocellular carcinoma: consider the population. , 2013, Journal of clinical gastroenterology.

[32]  J. Cai,et al.  Prognostic value of the albumin–bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[33]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[34]  M. Plummer,et al.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.

[35]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[36]  Gerhard Christofori,et al.  Distinct mechanisms of tumor invasion and metastasis. , 2007, Trends in molecular medicine.

[37]  K. Baggerly,et al.  Autocrine Effects of Tumor-Derived Complement , 2014, Cell reports.

[38]  Arnaud M. Vigneron,et al.  The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. , 2008, Cancer research.

[39]  W. Leonard,et al.  Interleukin-21: a double-edged sword with therapeutic potential , 2014, Nature Reviews Drug Discovery.

[40]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[41]  S. Horvath,et al.  Evidence for anti-Burkitt tumour globulins in Burkitt tumour patients and healthy individuals. , 1967, British Journal of Cancer.

[42]  Cynthia Gibas,et al.  Background correction using dinucleotide affinities improves the performance of GCRMA , 2008, BMC Bioinformatics.

[43]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[44]  Hans Skovgaard Poulsen,et al.  Mechanisms for oncogenic activation of the epidermal growth factor receptor. , 2007, Cellular signalling.

[45]  P. Schirmacher,et al.  Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. , 2017, The American journal of pathology.

[46]  A. Klein-Szanto,et al.  IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. , 2014, American journal of cancer research.

[47]  C. Koumenis ER stress, hypoxia tolerance and tumor progression. , 2006, Current molecular medicine.